| Vol. 9.13 – 6 April, 2021 |
| |
|
|
| Scientists found that patients with early natural killer cell activation after PEG–IFN-α injection experienced greater liver inflammation, lysis of HBV-infected hepatocytes, and hepatitis B surface antigen decline than those without. [Science Translational Medicine] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Human plasmacytoid dendritic cells produced high amounts of type I interferon when incubated with live cytomegalovirus-infected fibroblasts but not with free cytomegalovirus [Science Immunology] |
|
|
|
| Investigators showed downregulation of mitochondria-derived genes and mitochondria-associated metabolic pathways in IFN-High patients from transcriptomic analysis of CD4+ and CD8+ T cells. [Nature Communications] |
|
|
|
| Researchers showed that the N-terminal signal peptide was the major US9 functional domain targeting MICA*008 to proteasomal degradation. [Nature Communications] |
|
|
|
| To characterize glycosylphosphatidylinositol-anchored protein-deficient and HLA-class I allele-lacking hematopoietic stem progenitor cells in acquired aplastic anemia (AA), researchers studied the peripheral blood of 56 AA patients in remission. [Leukemia] |
|
|
|
| The authors present a comprehensive, temporal program of gene expression data encompassing human plasma cell differentiation using RNA sequencing [Leukemia] |
|
|
|
| Researchers showed that the IP3 receptor 3 and ITPKB, a kinase that converts IP3 to inositol 1,3,4,5-tetrakisphosphate, were both necessary for Ca2+ mobilization and NFAT activation in mouse and human dendritic cells. [Science Signaling] |
|
|
|
| Scientists used a protein conjugation system to produce a bispecific immune engager, V-aCD3, based on recombinant VAR2CSA as the cancer targeting moiety and an anti-CD3 single-chain variable fragment linked to a single-chain Fc as the immune engager. [Cell Death & Disease] |
|
|
|
| CTLA4-chimeric antigen receptor T cells were found to accumulate in tumors and are toxic to myeloid-derived suppressor cells without signs of severe graft-versus-host disease and cytokine release syndrome in preclinical models. [Frontiers in Immunology] |
|
|
|
|
| Scientists demonstrated that ZIP8 was specifically upregulated in CD4+ T cells that infiltrated the inflamed joint and that ZIP8 deficiency in CD4+ T cells abrogated collagen-induced arthritis. [Experimental & Molecular Medicine] |
|
|
|
|
| Sorrento Therapeutics, Inc. announced the signing of a merger agreement pursuant to which Sorrento will acquire ACEA Therapeutics, Inc. The acquisition will include late clinical stage drug Abivertinib, clinical stage candidate AC0058, preclinical stage candidate AC0939, and ACEA’s extensive proprietary library of small molecules, which potentially have applications for numerous human disease indications. [Sorrento Therapeutics, Inc. (Globe Newswire, Inc.)] |
|
|
|
| Kite announced that it has submitted a supplemental Biologics License Application to FDA for Tecartus® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. [Kite (BusinessWire, Inc.)] |
|
|
|
|
|
|
|
| University of Virginia – Charlottesville, Virginia, United States |
|
|
|
| Swiss Federal Institute of Technology in Lausanne – Lausanne, Switzerland |
|
|
|
| University of Toronto – Toronto, Ontario, Canada |
|
|
|
| H. Lee Moffitt Cancer Center & Research Institute – Tampa, Florida, United States |
|
|
|
| Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
|